EGFR T790M mutation testing within the osimertinib AURA phase I study.
AffiliationPersonalised Healthcare & Biomarkers, AstraZeneca, Cambridge
MetadataShow full item record
AbstractReliable epidermal growth factor receptor (EGFR) mutation testing techniques are required to identify eligible patients with EGFR mutation/T790M positive advanced non-small cell lung cancer (NSCLC), for treatment with osimertinib (AZD9291), an oral, potent, irreversible EGFR tyrosine kinase inhibitor (TKI) selective for EGFR-TKI-sensitizing and T790M resistance mutations over wild-type EGFR. There is no current consensus regarding the best method to detect EGFR T790M mutations. The aim of this study was to describe the concordance between local testing, which used a variety of methods, and central testing, using the cobas(®) EGFR Mutation Test, for EGFR-sensitizing mutations and the T790M resistance mutation.
CitationEGFR T790M mutation testing within the osimertinib AURA phase I study. 2017, 109:9-13 Lung Cancer